Sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells
Suppipat K, Park CS, Shen Y, Zhu X, Lacorazza HD
PloS one · 76 citas
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas, más trabajo en animales o laboratorio
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Gabrielle's Angel Foundation for Cancer Research
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2012-12-12 · PLoS One · vol. 7 · número 12 · pág. e51251
- Editorial
- Public Library of Science
- Citado
- 101 citas · más que el 99% de estudios similares · 9.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 63 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Acute Lymphoblastic Leukemia research · Genomics, phytochemicals, and oxidative stress · T-cell and Retrovirus Studies
- Palabras clave
- Sulforaphane, Protein kinase B, Cancer research, Apoptosis, PI3K/AKT/mTOR pathway, Medicine, Cell cycle checkpoint, Programmed cell death, Cyclin-dependent kinase 1, Cell cycle, Pharmacology, Cancer, Immunology, Oncology, Internal medicine, Biology, Biochemistry
- MeSH
- cell line, tumor, humans, thiocyanates, isothiocyanates, sulfoxides, cell cycle, apoptosis, precursor cell lymphoblastic leukemia-lymphoma
5 autores
- Koramit Suppipat🇺🇸Texas Children's Hospital
- Chun Shik Park🇺🇸Baylor College of Medicine
- Ye Shen🇺🇸Baylor College of Medicine
- Xiao Ping Zhu🇺🇸Baylor College of Medicine
- H. Daniel Lacorazza🇺🇸 · autor de correspondenciaBaylor College of Medicine
Resumen
El texto original del estudio, en el idioma en que se publicó.
Acute lymphoblastic leukemia (ALL) is the most common hematological cancer in children. Although risk-adaptive therapy, CNS-directed chemotherapy, and supportive care have improved the survival of ALL patients, disease relapse is still the leading cause of cancer-related death in children. Therefore, new drugs are needed as frontline treatments in high-risk disease and as salvage agents in relapsed ALL. In this study, we report that purified sulforaphane, a natural isothiocyanate found in cruciferous vegetables, has anti-leukemic properties in a broad range of ALL cell lines and primary lymphoblasts from pediatric T-ALL and pre-B ALL patients. The treatment of ALL leukemic cells with sulforaphane resulted in dose-dependent apoptosis and G2/M cell cycle arrest, which was associated with the activation of caspases (3, 8, and 9), inactivation of PARP, p53-independent upregulation of p21(CIP1/WAF1), and inhibition of the Cdc2/Cyclin B1 complex. Interestingly, sulforaphane also inhibited the AKT and mTOR survival pathways in most of the tested cell lines by lowering the levels of both total and phosphorylated proteins. Finally, the administration of sulforaphane to the ALL xenograft models resulted in a reduction of tumor burden, particularly following oral administration, suggesting a potential role as an adjunctive agent to improve the therapeutic response in high-risk ALL patients with activated AKT signaling.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.